Abacus Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Abacus Wealth Partners's VRTX Position: Q2 2026 in Review
Abacus Wealth Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 54% in Q2 2026, selling an estimated $423K and leaving 798 shares worth $396K. The position accounts for 0.04% of the portfolio, ranked #190.
Abacus Wealth Partners first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $783K in Q1 2026. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Abacus Wealth Partners held 798 shares of Vertex Pharmaceuticals worth $396K as of Q2 2026.
- Abacus Wealth Partners sold 955 Vertex Pharmaceuticals shares in Q2 2026, an estimated $423K.
- Vertex Pharmaceuticals made up 0.04% of Abacus Wealth Partners's portfolio in Q2 2026, its #190 holding.
- Abacus Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- Abacus Wealth Partners's Vertex Pharmaceuticals position peaked at $783K in Q1 2026.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.